Keros Therapeutics
Yahoo Finance • 2 months ago
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Nurix Therapeutics, Inc. (NRIX) shares soared 16.4% in the last trading session to close at $22.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.5% gain o... Full story
- NRIX
Mentioned:
Yahoo Finance • 2 months ago
Keros Appoints Anne Prener To Board Of Directors
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, announced on Thursday the appointment of Anne Prener to its Board of Directors, effective from July 1, 2026. Prener currently serves as a Senior Inno... Full story
- NVO
Mentioned:
Yahoo Finance • 2 months ago
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story
Yahoo Finance • 9 months ago
Keros Therapeutics Announces Final Results of Tender Offer
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares... Full story
Yahoo Finance • 9 months ago
Keros Therapeutics Announces Preliminary Results of Tender Offer
LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165... Full story
Yahoo Finance • 10 months ago
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares
* Keros Therapeutics (NASDAQ:KROS [https://seekingalpha.com/symbol/KROS]) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per share. The Company expects to fund the ten... Full story
Yahoo Finance • 10 months ago
Keros Therapeutics To Buyback $181 Mln Of Shares From ADAR1, Pontifax; Plans $194 Mln Tender Offer
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, on Wednesday announced that it has entered into share purchase agreements to buy back all shares held by ADAR1 Capital Management LLC and Pontifax Ven... Full story
- TAK
Mentioned:
Yahoo Finance • 10 months ago
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- K... Full story
Yahoo Finance • 12 months ago
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story
Yahoo Finance • 12 months ago
Sector Update: Health Care Stocks Rise Pre-Bell Friday
Health care stocks were rising pre-bell Friday, with The Health Care Select Sector SPDR Fund (XLV) 0 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 12 months ago
Keros Therapeutics' Duchenne Muscular Dystrophy Treatment Gets FDA's Orphan Drug Designation
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, Wednesday announced that the U.S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dyst... Full story
Yahoo Finance • 12 months ago
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story
Yahoo Finance • last year
Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright
Investing.com - H.C. Wainwright lowered its price target on Keros Therapeutics (NASDAQ:KROS) to $20.00 from $25.00 on Friday, while maintaining a Buy rating on the stock. According to InvestingPro data, the stock appears undervalued at cur... Full story
Yahoo Finance • last year
Keros earnings beat by $0.37, revenue topped estimates
Investing.com - Keros (NASDAQ: KROS) reported second quarter EPS of $-0.76, $0.37 better than the analyst estimate of $-1.13. Revenue for the quarter came in at $18.17M versus the consensus estimate of $4.21M. Keros’s stock price closed a... Full story
Yahoo Finance • last year
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Ker... Full story
Yahoo Finance • last year
Keros Therapeutics Reports Second Quarter 2025 Financial Results
LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story
Yahoo Finance • last year
Keros Announces Return of $375 Million in Excess Capital to Stockholders
LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story
Yahoo Finance • last year
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story
Yahoo Finance • last year
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH) on Wednesday. In December 2024... Full story
- MRK